Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats

Psychopharmacology

Volumn 231, Issue 18, 2014, Pages 3695-3706

  Callahan, Patrick M ^a   Terry, Alvin V ^a   Tehim, Ashok ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Dr Reddy's Laboratories   (United States)

Author keywords

Cognition; Nicotinic 7 receptor; NMDA glutamate function; Object recognition memory; Schizophrenia; Sensorimotor gating

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; APOMORPHINE; BUNGAROTOXIN RECEPTOR; CLOZAPINE; DIZOCILPINE; HALOPERIDOL; METHYLLYCACONITINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; 3-(2,4-DIMETHOXYBENZYLIDENE)ANABASEINE; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; BENZYLIDENE DERIVATIVE; DIZOCILPINE MALEATE; NICOTINIC AGENT; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; IN VIVO STUDY; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RECOGNITION; SENSORY GATING; STARTLE REFLEX; AGONISTS; ANIMAL; COGNITION; DRUG EFFECTS; PHYSIOLOGY; SPRAGUE DAWLEY RAT; WISTAR RAT;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; APOMORPHINE; BENZYLIDENE COMPOUNDS; CLOZAPINE; COGNITION; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; GABA ANTAGONISTS; HALOPERIDOL; MALE; NICOTINIC AGONISTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; RECOGNITION (PSYCHOLOGY); REFLEX, STARTLE; SENSORY GATING;

EID: 84906934395     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3509-2     Document Type: Article

References (92)

1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K et al (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189-202 (Pubitemid 28404980)
2. Ainge JA, Heron-Maxwell C, Theofilas P, Wright P, de Hoz L, Wood ER (2006) The role of the hippocampus in object recognition in rats: examination of the influence of task parameters and lesion size. Behav Brain Res 167:183-195 (Pubitemid 43063154)
3. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP et al (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16:19-30 (Pubitemid 26010694)
4. Aleman A, Hijmann R, de Haan EH, Kahn RS (1999) Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358-1366 (Pubitemid 29416531)
5. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674:252-259
6. Barker GRI, Bird F, Alexander V, Warburton EC (2007) Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. J Neurosci 27:2948-2957 (Pubitemid 46438982)
7. Beneyto M, Meador-Woodruff JH (2008) Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33:2175-2186 (Pubitemid 351992080)
8. Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S et al (2010) In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther 334:875-886
9. Braff DL, Light GA (2004) Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology 174:75-85 (Pubitemid 38925093)
10. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156:234-258 (Pubitemid 32705488)
11. Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campell JE et al (1997) Functional characterization of the novel neuronal nicotinic receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57:231-241 (Pubitemid 27261416)
12. Buccafusco JJ, Terry AV Jr (2009) A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 78:852-862
13. Buffalo EA, Bellgowan PS, Martin A (2006) Distinct roles for medial temporal lobe structure in memory for objects and their locations. Learn Mem 13:638-643 (Pubitemid 44498416)
14. Callahan PM, Wang S, Xie W, Dragan S, Sun S, Michael T et al (2006) Pharmacological characterization of MEM 3454, a novel nicotinic alpha7 receptor partial agonist: therapeutic potential for the cognitive deficits associated with Alzheimer's disease and schizophrenia. Neuropsychopharmacology 32:S198
15. Callahan PM, Hutchings EJ, Kille NJ, Chapman JM, Terry AV Jr (2013) Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology 67:201-212
16. Cannon CE, Puri V, Vivian JA, Egbertson MS, Eddins D, Uslaner JM (2013) The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. Neuropharmacology 64:191-196
17. Clark RE, Zola SM, Squire LR (2000) Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20:8853-8860
18. De Lima MN, Laranja DC, Bromberg E, Roesler R, Schroeder N (2005) Pre- or post-training administration of the NMDA receptor blocker Mk-801 impairs object recognition memory in rats. Behav Brain Res 156:139-143 (Pubitemid 39330444)
19. (2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5- b′]di pyrrole-1(2H)-carboxamide). J Pharmacol Exp Ther 328:766-776
20. Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31:47-59
21. Exner C, Nehrkorn B, Martin V, Huber M, Shiratori K, Rief W (2008) Sex-dependent hippocampal volume reductions in schizophrenia relate to episodic memory deficits. J Neuropsychiatry Clin Neurosci 20:227-230
22. Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG, Fine A (2001) Ultrastructual distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 21:7993-8003 (Pubitemid 32952756)
23. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L et al (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040-1047
24. George TP, Termine A, Sacco KA, Allen TM, Reutenauer E et al (2006) A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr Res 87:307-315 (Pubitemid 44462734)
25. Geyer MA, Braff DL (1987) Startle habituation and sensorimotor gating in schizophrenia and related animals models. Schizophr Bull 13:643-668 (Pubitemid 18037659)
26. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154 (Pubitemid 32702206)
27. Ghiron C, Haydar SN, Aschmies S, Bothmann H, Castaldo C et al (2010) Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl) pyridine-3-yl]-3-(4-piperidin-1- ylbutyl) urea (SEN34625/WYE-103914). J Med Chem 53:4379-4389
28. Goff DC, Wine L (1997) Glutamate in schizophrenia: clinical and research implications. Schizophr Res 27:157-168 (Pubitemid 27512852)
29. Green MF, Braff DL (2001) Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry 49:374-384 (Pubitemid 32182368)
30. Hajos M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, Groppi VE (2005) The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabiyclo[2.2.2]oct-3-yl]-4-chlorbenzamide hydrochloride] enhances GABergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized. J Pharmacol Exp Ther 312:1213-1222 (Pubitemid 40293783)
31. Hashimoto K, Iyo M, Freedman R, Stevens KE (2005) Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors. Psychopharmacology 183:13-19 (Pubitemid 41484178)
32. Hashimoto K, Fujita Y, Ishima T, Hagiwara H, Iyo M (2006) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of α7 nicotinic receptors. Eur J Pharmacol 553:191-195 (Pubitemid 44779614)
33. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobahis T et al (2008) Phencyclidine-induced cognitive defects in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63:92-97 (Pubitemid 350234890)
34. Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA et al (2009) TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78:803-812
35. Hilt D, Gawryl M, Koenig G (2009) EVP-6124: safety, tolerability and cognitive effects of a novel A7 nicotinic receptor agonist in Alzheimer 's disease patients on stable donepezil or rivastigmine therapy. Alzheimers Dement 5:e32
36. Hong LE, Wonodi I, Lewis J, Thaker GK (2008) Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology 33:2167-2174 (Pubitemid 351992077)
37. Huang M, Meltzer H, Felix A, Panos J, Van Goethem N, Bertrand S et al (2011) EVP-6124, an alpha-7 nicotinic receptor partial agonist enhances cognition and efflux of dopamine, acetylcholine and glutamate in rat cortex at low brain concentrations. Neuropsychopharmacology 37:S184
38. Hurst R, Rollema H, Bertrand D (2013) Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 137:22-54
39. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsycholopharmacol Biol Psychiatry 27:1081-1090 (Pubitemid 37464954)
40. Kem WR (2000) The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 113:169-181
41. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, Burnett AL (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28:542-551
42. Kohnomi S, Suemaru K, Goda M, Choshi T et al (2010) Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the α7 nicotinic acetylcholine receptor in Wistar rats. Brain Res 1353:152-158
43. Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H et al (2005) Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 76:67-72 (Pubitemid 40824561)
44. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77:231-236
45. Kumari V, Soni W, Sharma T (2001) Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. Hum Psychopharmacol 16:321-326 (Pubitemid 32655166)
46. Kumari V, Gray JA, Geyer MA, Ffytche D, Soni W, Mitterschiffthaler MT et al (2003) Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res 122:99-113 (Pubitemid 36511394)
47. Larrauri JA, Levin ED (2012) The α2-adrenergic antagonist idazoxan counteracts prepulse inhibition deficits caused by amphetamine and dizocilpine in rats. Psychopharmacology 219:99-108
48. Lathi AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467 (Pubitemid 32830950)
49. Levin ED, Caldwell DP, Perraut C (2007) Clozapine treatment reverses dizocilpine-induced deficits of pre-pulse inhibition of tactile startle response. Pharmacol Biochem Behav 86:597-605 (Pubitemid 46466893)
50. Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS et al (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38:968-975
51. Lyon L, Saksida LM, Bussey TJ (2012) Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacology 220:647-672
52. Malhortra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150 (Pubitemid 27365955)
53. Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308 (Pubitemid 20025258)
54. Mansbach RS, Carver J, Zorn SH (2001) Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav 69:535-542 (Pubitemid 32758739)
55. McLean SL, Grayson B, Idris NF, Lesage AS, Pemberton D et al (2011) Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol 21:333-343
56. Meltzer HY, Gawryl M, Ward S, Dgetluck N, Bhuvaneswaran C, Koenig G et al (2011) EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. Neuropsychopharmacology 37:S170
57. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL et al (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432
58. Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR et al (2013) A placebocontrolled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychophramacology 228:595-602
59. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D et al (2006) Proof of concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-638 (Pubitemid 43848294)
60. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. J Psychiat Res 33:523-533
61. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V et al (2007) SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34 (Pubitemid 44967781)
62. Prickaerts J, Van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C et al (2012) EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 62:1099-1110
63. Rabin RA, Sacco KA, George TP (2009) Correlation of prepulse inhibition and Wisconsin card sorting test in schizophrenia and controls: effects of smoking status. Schizophr Res 114:91-97
64. Radcliffe KA, Fisher JL, Gray R, Dani JA (1999) Nicotinic modulation of glutamate and GABA synaptic transmission in hippocampal neurons. Ann N YAcad Sci 30:591-610 (Pubitemid 29281171)
65. Radek RJ, Robb HM, Stevens KE, Gopalakrishnan M, Biner RS (2012) Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization. J Pharmacol Exp Ther 343:736-745
66. Ranganath C, Minzenberg MJ, Ragland JD (2008) The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol Psychiatry 64:18-25
67. Reed JM, Squire LR (1997) Impaired recognition memory in patients with lesions limited to the hippocampal formation. Behav Neurosci 111:667-675 (Pubitemid 27335378)
68. Rezvani AH, Kholdebarin E, Brucato FH, Callahan PM, Lowe DA, Levin ED (2009) Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry 33:269-275
69. Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070-1076 (Pubitemid 40461058)
70. Rodefer JS, Baseile JL, Callahan PM, Van Natta K, Yeo H, Lowe DA et al (2007) Attentional set-shifting in rats and monkeys: effects of cholinergic challenges. Soc Neurosci Abstr p746.4
71. Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H et al (2009) Procognitive and neuroprotective activity of a novel α7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 329:459-468
72. Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141
73. Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T et al (2010) A randomized, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry 9:27
74. Skidmore J, Atcha Z, Boucherat E, Castelletti L, Chen DW, Coppo FT et al (2012) The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1, 3,4-oxadiazol-2yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement. Bioorg Med Chem Lett 22:3531-3534
75. Squire LR, Stark CE, Clark RE (2004) The medial temporal lobe. Ann Rev Neurosci 27:279-283
76. Stevens KE, Kem WR, Mahnir VM, Freedman R (1998) Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136:320-327 (Pubitemid 28189660)
77. Sullivan PF (2012) Puzzling over schizophrenia: schizophrenia as a pathway disease. Nat Med 18:210-211
78. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 56:194-215 (Pubitemid 32702213)
79. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL (2006) Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63:1325-1335 (Pubitemid 44878517)
80. Synder MA, Gao WJ (2013) NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci 7:1-12
81. Terry AV Jr, Parikh V, Gearhart DA, Pilai A, Hohnadel E et al (2006) Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats. J Pharmacol Exp Ther 318:709-724 (Pubitemid 44061246)
82. Terry AV Jr, Gearhart DA, Warner SE, Zhang G, Bartlett MG, Middlemore ML et al (2007) Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholingeric neurons, and memory performance. Neuroscience 146:1316-1332 (Pubitemid 46711147)
83. Timofeeva OA, Levin ED (2011) Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia. Neuroscience 195:21-36
84. Turetsky BI, Moberg PJ, Roalf DR, Arnold SE, Gur RE (2003) Decrements in volume of anterior ventromedical temporal lobe and olfactory dysfunction in schizophrenia. Arch Gen Psychiatry 60:1193-1200 (Pubitemid 37494072)
85. Umbricht DMS, Lowe D, Yoo K, Porter R, Garibaldi G, Santarelli L et al (2009) The effect of the partial nicotinic alpha7 receptor agonist R3487 on cognitive deficits in schizophrenia. Neuropsychopharmacology 35:S187
86. Wallace TL, Bertrand D (2013) Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin Ther Targets 17:139-155
87. Wallace TL, Porter RHP (2011) Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition. Biochem Pharmacol 82:891-903
88. Wallace TL, Chiu G, Dao H, Santarelli L, Porter R, Bertrand S, Bertrand D (2010) Modulation of cholinergic tone impacts the efficacy of RG3487/MEM3454, a novel, nicotinic alpha 7 receptor agonist. Soc Neurosci Abstr p236.1
89. Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S et al (2011) RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 336:242-253
90. Wallace-Boone TL, Chui G, Dao H, Lowe DA, Porter R, Santarelli L (2009) R3487/MEM3454, a novel nicotinic alpha 7 receptor partial agonist, improves attention and working memory performance in cynomolgus macaques. Soc Neurosci Abstr p887
91. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150-202
92. Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH et al (2012) Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry 169:974-981